Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders.
Provide less toxic and potentially life-saving mental health interventions for people who are already using medications to treat mental health disorders. Through expedited efficacy trials, and drug development/ research and development intellectual property, Mindset hopes to pursue efficacy trials for psilocybin analogs to determine the best use-cases for psychedelic intervention. The goal is to provide long-lasting mental health relief and provide alternatives to existing pharma options.
Milestones & Timelines.
- Mindset Files Articles of Incorporation And Elects Board Of Directors
- Mindset Adds Medicinal Chemist to Scientific Advisory Team
- Mindset Pharm Files Groundbreaking Psychedelic Patents
- Mindset Pharma Engages InterVivo Solutions for Initial Drug Analysis
- Mindset Completes Private Placement Financing
- Mindset Pharma Begins Work with Leading R&D Contractor for Next-Generation Psychedelic Drugs
- Mindset Pharma Synthesizes Second Generation Medicinal Psychedelic Compounds
Topics for Discussion.
Here are some of the topics Mindset CEO, James Lanthier, is ready to discuss.
- Drug Discovery and Intellectual Property development in research.
- Psychedelic Medicine in Mental Health
- Canadian Psychedelics and the hunt for novel compounds.
- Learnings from being First Movers in the Psychedelic Space
- Psilocybin Investment Opportunities in Canadian “Mush Rush”
- Covid-19 and the After Effects of Isolation on mental health in Canada
- Drug-resistant PTSD, Depression and Addiction
- Economy in Canada
Here are some of the topics Mindset Scientist, Malik Slassi, is ready to discuss.
- The Pre-Clinical Trial Process and where we are at in terms of determining medical efficacy for psychedelic interventions
- Organic versus Synthetic Molecules
- Drug Discovery Timeline
Chief Science Officer & Director
President and CEO of InterVivo Solutions, which is focused on optimizing translational services to facilitate the development and approval of novel CNS drugs. Graduate training in pharmacology at the University of Toronto. More than 35 refereed publications and several invited presentations, which focus on natural aged canine models of human disease. Has co-founded, held executive-level positions and consulted for Life Science companies including CanCog Technologies, Vivocore, Karyopharm Therapeutics, NPM Pharma, Ketogen, and Epione Animal Health. Has done extensive research examining psychoactive drugs.
Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. Over 30 years of experience in the successful identification and development of small molecule drug candidates across multiple therapeutic areas. Former Director and Vice President of Medicinal Chemistry and Manufacturing & Drug Development at NPS Pharmaceuticals and Cascade Therapeutics respectively. Worked on numerous multinational R&D collaborations including with Hoechst AG (Sanofi-Aventis), AstraZeneca, Johnson & Johnson, Forest Laboratories, GlaxoSmithKline, and Memory Pharmaceuticals.
Strong track record of drug development with over 20 drug candidates advanced into late-stage preclinical, clinical development and market. An inventor with over 130 issued and published patents and patent applications, and author of more than 65 scientific and review articles published in international peer-reviewed journals. Holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.
Management & Board of Directors.
A seasoned technology executive with strong expertise in corporate finance, public markets and M&A. Most recently, Mr. Lanthier was a co-founder and CEO of Future Fertility, an innovative early-stage developer of AI applications for human infertility. As a C-Suite executive, Mr. Lanthier has assisted in the growth and successful exit of numerous technology-enabled businesses through the public markets, including Mood Media, the world’s largest in-store media provider, and Fun Technologies, a pioneer in online casual games.
VP Corporate Development
A finance professional with experience in private equity, venture capital, investment banking and corporate finance. He has played a key role in raising capital and providing advisory services to private and publicly listed entities across multiple industries. He holds an MBA from the Degroote School of Business and is a CFA Charterholder.
A 19-year hedge fund and private equity fund veteran with a deep experience in emerging market equities and venture capital. James is a director of BDSec JSC, the largest investment bank in Mongolia, where he was awarded the Friendship Medal by the Mongolian state. Formerly a Principal at New York-based Firebird Management LLC, James has been called a “Daredevil Investor” by the New York Times and “the Indiana Jones of Frontier Stock Markets” by the Financial Times.
Qualified lawyer (Ontario) with over 15 years of experience working with and for public companies. He has built a number of mining companies with global operations and spent 10 years with a TSX-listed investment company focused on the early-stage investment space. Mr. Patricio holds and has held senior officer and director positions in several companies that are listed on the TSX, ASX, NYSE and AIM exchanges.
More than 20 years of finance industry experience. His diverse experience includes roles as C-Suite Executive, as a sell-side research analyst, in fund management, managing director of investment banking and sits on the Board of several public companies in Canada.